Cellular Bio to present AlloJoin data at China conference tomorrow

Cellular Biomedicine Group (NASDAQ:CBMG) plans to present 48-week data from a Phase 1 clinical trial assessing its AlloJoin allogeneic human adipose-derived mesenchymal progenitor cell off-the-shelf therapy for osteoarthritis of the knee tomorrow at the B. Riley FBR China Healthcare Investing & Partnering Symposium in Hangzhou, China.

Nguồn: seekingalpha.com